Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial

Author(s):: McClung, M.R.; Langdahl, B.; Papapoulos, S.; Saag, K.G.; Adami, S.; Bone, H.G.; Villiers, T. de; Kiel, D.P.; Kung, A.; Kumar, P.; Lim, S.K.; Ling, X.; Lippuner, K.; Mautalen, C.; Nakamura, T.; Reginster, J.Y.; Reid, I.R.; Rodriguez-Portales, J.A.; Roux, C.; Walliser, J.; Watts, N.B.; Zanchetta, J.R.; Zerbini, C.A.F.; Rybak-Feiglin, A.; Cohn, D.; DaSilva, C.A.; Massaad, R.; Santora, A.; Scott, B.B.; Verbruggen, N.; Leung, A.; Lombardi, A.